Faes Farma

Spanish pharmaceutical company

ISIN ES0134950F36 LEI 959800FXZQY7U3P1G969
Follow Faes Farma Weekly email: filings, results

Financials

Reported figures only · latest: fiscal 2025 EUR · IFRS
Revenue, last year €610.5M +23.7% vs prior year
Net income €79.6M −28.5% vs prior year
EPS, diluted €0.25 −28.7% vs prior year
Operating cash flow €78.5M −32% vs prior year
Revenue by fiscal year
€380.2M
€398.6M
€438.8M
€451.2M
€493.6M
€610.5M
FY20 FY21 FY22 FY23 FY24 FY25

Source: ESEF annual reports · latest filing

The long view

Fiscal years as reported · ESEF annual reports, IFRS
Revenue and net income7 fiscal years
  • Revenue
  • Net income
€0€200M€400M€600M€800MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25€610.5M€79.6M
FY24€493.6M€111.4M
FY23€451.2M€91.9M
FY22€438.8M€89.6M
FY21€398.6M€82.4M
FY20€380.2M€72.5M
FY19€357.4M€64M
MarginsShare of revenue
0%10%20%30%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet margin
FY2513%
FY2422.6%
FY2320.4%
FY2220.4%
FY2120.7%
FY2019.1%
FY1917.9%
Free cash flowOperating cash flow minus capital expenditure
€0€25M€50M€75M€100MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25€62.4M
FY24€81.7M
FY23€5.2M
FY22€31.6M
FY21€28.2M
FY20€58.3M
FY19€50.6M
Returned to shareholdersDividends paid and shares bought back
  • Dividends
  • Buybacks
€0€20M€40M€60MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearDividendsBuybacks
FY25€55.7M-
FY24€48.2M-
FY23€14.6M-
FY22€18.1M-
FY21€13.7M-
FY20€12.2M€92K
FY19€10.3M€2.8M
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Faes Farma
  • Healthcare median
−100%−50%0%50%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFaes FarmaHealthcare median
FY2513%−30.6%
FY2422.6%−47%
FY2320.4%−58%
FY2220.4%−80.4%
FY2120.7%−71.9%
FY2019.1%−62.2%
FY1917.9%−46.3%